scholarly journals Novel Lipid Species for Detecting and Predicting Atrial Fibrillation in Patients With Type 2 Diabetes

Diabetes ◽  
2020 ◽  
Vol 70 (1) ◽  
pp. 255-261
Author(s):  
Yow Keat Tham ◽  
Kaushala S. Jayawardana ◽  
Zahir H. Alshehry ◽  
Corey Giles ◽  
Kevin Huynh ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Type 2 Diabetes ◽  
Lipid Species

scholarly journals Novel lipid species for detecting and predicting atrial fibrillation in patients with type 2 diabetes

2020 ◽  
Author(s):  
Ada Admin ◽  
Yow Keat Tham ◽  
Kaushala S. Jayawardana ◽  
Zahir H. Alshehry ◽  
Corey Giles ◽  
...  
Keyword(s):  
Risk Factors ◽  
Atrial Fibrillation ◽  
Type 2 Diabetes ◽  
Mouse Model ◽  
Plasma Lipids ◽  
Lipid Analysis ◽  
Logistic Regression Models ◽  
Lipid Species ◽  
Patients With Diabetes

The incidence of atrial fibrillation (AF) is higher in patients with diabetes. The goal of this study was to assess if the addition of plasma lipids to traditional risk factors could improve the ability to detect and predict future AF in patients with type 2 diabetes. Logistic regression models were used to identify lipids associated with AF/future AF from plasma lipids (n=316) measured from participants from the ADVANCE trial (n=3,772). To gain mechanistic insight, follow-up lipid analysis was undertaken in a mouse model which has an insulin-resistant heart and is susceptible to AF. Sphingolipids, cholesteryl esters and phospholipids were associated with AF prevalence, whereas two G<sub>M3</sub> ganglioside species were associated with future AF. For AF detection and prediction, addition of 6 and 3 lipids, respectively, to a base model (12 conventional risk factors) increased the C-statistics (detection:0.661 to 0.725; prediction:0.674 to 0.715), and categorical net reclassification indices. GM3(d18:1/24:1) was lower in patients who developed AF, improved the C-statistic for the prediction of future AF, and was lower in the plasma of the mouse model susceptible to AF. This study demonstrates that plasma lipids have the potential to improve both the detection and prediction of AF in patients with diabetes.

scholarly journals Novel lipid species for detecting and predicting atrial fibrillation in patients with type 2 diabetes

2020 ◽  
Author(s):  
Ada Admin ◽  
Yow Keat Tham ◽  
Kaushala S. Jayawardana ◽  
Zahir H. Alshehry ◽  
Corey Giles ◽  
...  
Keyword(s):  
Risk Factors ◽  
Atrial Fibrillation ◽  
Type 2 Diabetes ◽  
Mouse Model ◽  
Plasma Lipids ◽  
Lipid Analysis ◽  
Logistic Regression Models ◽  
Lipid Species ◽  
Patients With Diabetes

The incidence of atrial fibrillation (AF) is higher in patients with diabetes. The goal of this study was to assess if the addition of plasma lipids to traditional risk factors could improve the ability to detect and predict future AF in patients with type 2 diabetes. Logistic regression models were used to identify lipids associated with AF/future AF from plasma lipids (n=316) measured from participants from the ADVANCE trial (n=3,772). To gain mechanistic insight, follow-up lipid analysis was undertaken in a mouse model which has an insulin-resistant heart and is susceptible to AF. Sphingolipids, cholesteryl esters and phospholipids were associated with AF prevalence, whereas two G<sub>M3</sub> ganglioside species were associated with future AF. For AF detection and prediction, addition of 6 and 3 lipids, respectively, to a base model (12 conventional risk factors) increased the C-statistics (detection:0.661 to 0.725; prediction:0.674 to 0.715), and categorical net reclassification indices. GM3(d18:1/24:1) was lower in patients who developed AF, improved the C-statistic for the prediction of future AF, and was lower in the plasma of the mouse model susceptible to AF. This study demonstrates that plasma lipids have the potential to improve both the detection and prediction of AF in patients with diabetes.

scholarly journals CARDIORESPIRATORY FITNESS LOWERS THE RISK FOR ATRIAL FIBRILLATION IN MEN WITH TYPE 2 DIABETES MELLITUS

2014 ◽  
Vol 63 (12) ◽  
pp. A365
Author(s):  
Andreas Pittaras ◽  
Michael E. Doumas ◽  
Charles Faselis ◽  
F. Kyritsi ◽  
JP Kokkinos ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Atrial Fibrillation ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Cardiorespiratory Fitness

scholarly journals Risk of atrial fibrillation development of sodium-glucose co-transporter 2 inhibitor and thiazolidinedione treatment among patients with type 2 diabetes

2021 ◽  
Vol 42 (Supplement_1) ◽  
Author(s):  
Y.R Kim ◽  
S.E Lee ◽  
K.A Kim
Keyword(s):  
Atrial Fibrillation ◽  
Type 2 Diabetes ◽  
Incidence Rates ◽  
Good Choice ◽  
Diabetic Patients ◽  
Funding Sources ◽  
Korean National Health Insurance ◽  
Outcome Event

Abstract Background Type 2 diabetes is an independent risk factor for the development of atrial fibrillation (AF). Recently, SGLT-2i has been shown to decrease the incidence of AF through several mechanisms including reduction of atrial dilatation via diuresis and lowering body weight. On the other hand, the use of TZD was found to protect diabetic patients from new-onset AF in observational studies. Thus, we aimed to compare the effect of SGLT-2i and TZD on the risk of AF development. Methods Using the Korean National Health Insurance Service database, we included patients with type 2 diabetes who were prescribed SGLT-2i or TZD at least once from January 2014 to December 2018. Patients were followed until the outcome event, death, or 31 December 2018. Sensitivity analysis was performed only including patients who prescribed study drugs ≥90 days. Results A total of 206,986 patients were included (88,227 patients in SGLT-2i group and 118,759 in TZD group). Baseline characteristics were mean age was 57 years and 57.4% were male; mean body mass index was 26.3kg/m2 and 68.3% had hypertension. During follow-up, the incidence rates of AF were 1.36% in SGLT-2i-treated patients and 0.87% TZD-treated patients, respectively (p=0.0002). The hazard ratio (HR) of AF was 0.846 (95% confidence interval [CI]: 0.0.775–0.923) in SGLT-2i-treated patients compared with TZD-treated patients. Conclusions In this study, the risk of AF development was significantly lower in patients treated with SGLT-2i versus TZD. SGLT2 would be a good choice for the patients with high risk of AF development among diabetes mellitus. FUNDunding Acknowledgement Type of funding sources: None.

Sign in / Sign up

Export Citation Format

Share Document